Skip to main content
森萱医药 logo

森萱医药 — Investor Relations & Filings

Ticker · 920946 Beijing Stock Exchange Manufacturing
Open in API
Filings indexed 417 across all filing types
Latest filing 2024-05-13 Board/Management Inform…
Country CN China
Listing Beijing Stock Exchange 920946

About 森萱医药

https://www.senxuan.cn/

Jiangsu Senxuan Pharmaceutical Co., Ltd. specializes in the research, development, and production of pharmaceutical intermediates, active pharmaceutical ingredients (APIs), and specialized fine chemicals. The company’s product portfolio includes key intermediates for antiviral medications, such as those used in the treatment of HIV, and anticonvulsant agents like Primidone. Additionally, it produces high-purity chemical solvents including 1,4-dioxane and 1,3-dioxolane for diverse industrial applications. Senxuan Pharmaceutical maintains a focus on advanced chemical synthesis and large-scale manufacturing capabilities, adhering to international quality standards to support the global life sciences and chemical sectors. Its operations are characterized by a commitment to technical innovation and the supply of critical chemical building blocks for complex therapeutic formulations.

Recent filings

Filing Released Lang Actions
第四届董事会第四次会议决议公告
Board/Management Information Classification · 100% confidence The document is a formal announcement of resolutions passed at the fourth meeting of the fourth board of directors of Jiangsu Senxuan Pharmaceutical Co., Ltd. It details the meeting date, attendance, agenda items, and voting results. The content focuses on board decisions such as the appointment of the accounting firm and the calling of an extraordinary shareholders' meeting. There is no financial data, earnings information, or detailed report content. The document is clearly an announcement of board meeting resolutions, which fits the category of Board/Management Information (MANG). The document length is short (1330 characters), and it is not a report or presentation but a formal announcement of board decisions.
2024-05-13 Chinese
第四届监事会第四次会议决议公告
Board/Management Information Classification · 95% confidence The document is a resolution announcement from the Supervisory Board (监事会) of Jiangsu Senxuan Pharmaceutical Co., Ltd. It details the convening and attendance of the fourth meeting of the fourth Supervisory Board, including the approval of a proposal to appoint an accounting firm for 2024. The document references a related announcement published on the Beijing Stock Exchange information disclosure platform. The content is about a board meeting decision and does not contain financial statements or detailed financial data. It is not an annual report, audit report, or financial report. It is also not a regulatory filing or a report publication announcement since it contains substantive meeting resolution content. The document fits best under Board/Management Information (MANG) as it concerns board-level decisions and appointments.
2024-05-13 Chinese
关于召开2024年第一次临时股东大会通知公告（提供网络投票）
Proxy Solicitation & Information Statement Classification · 95% confidence The document is a notice announcing the convening of the 2024 first extraordinary general meeting of shareholders (临时股东大会) for Jiangsu Senxuan Pharmaceutical Co., Ltd. It details the meeting date, voting methods (including online voting), attendees, agenda items, and registration procedures. It does not contain financial statements, audit results, or detailed financial data. The document is primarily an announcement about the meeting itself, not the meeting materials or results. Therefore, it fits the category of a Proxy Solicitation & Information Statement (PSI), which includes materials sent to shareholders to provide information and request votes for meetings.
2024-05-13 Chinese
关于增设募集资金专户并签署三方监管协议的公告
Capital/Financing Update Classification · 95% confidence The document is a public announcement from Jiangsu Senxuan Pharmaceutical Co., Ltd. regarding the establishment of new special accounts for raised funds and the signing of tripartite supervision agreements related to the management and use of these funds. It details the amounts raised, the use of funds, and the parties involved in the supervision agreements. There is no financial statement, earnings data, or detailed financial analysis present. The document is relatively short (1620 characters) and serves as an update on capital management and regulatory compliance related to fundraising activities. This fits the definition of a Capital/Financing Update (CAP) rather than a full financial report or other categories.
2024-05-12 Chinese
关于投资者关系活动记录表的公告
Call Transcript Classification · 95% confidence The document is titled as an "投资者关系活动记录表" which translates to "Investor Relations Activity Record". It specifically mentions that the company held an "业绩说明会" (performance explanation meeting) on May 7 and May 10, 2024, to discuss the 2023 annual report. The content consists of Q&A between investors and company representatives about the company's 2023 financial performance, project progress, ESG report plans, and other operational matters. This matches the characteristics of a Call Transcript (CT) or an Investor Presentation (IP). However, since it is a record of an investor relations activity focused on explaining the annual report and answering questions, and it is not a formal presentation slide deck, it aligns best with a Call Transcript (CT) type document. The document length is 2347 characters, which is consistent with a transcript rather than a full annual report or presentation. Therefore, the classification is Call Transcript (CT).
2024-05-12 Chinese
2024年一季度报告
Interim / Quarterly Report Classification · 95% confidence The document is titled as the "2024 年第一季度报告" which translates to "2024 First Quarter Report". It contains detailed financial data including consolidated balance sheets, profit and loss statements, cash flow statements, and notes on financial performance for the period January to March 2024. The report explicitly states it is unaudited and covers a quarterly period, with comprehensive financial figures and analysis. This matches the definition of an Interim / Quarterly Report (IR), which is a comprehensive financial report for a period shorter than a full fiscal year containing actual financial statements and substantive financial data. The document is about 15,000 characters long, which is consistent with a full report rather than a brief announcement or certification. Therefore, the correct classification is IR with high confidence. Q1 2024
2024-04-28 Chinese

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.